A detailed history of Captrust Financial Advisors transactions in Exelixis, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 35,430 shares of EXEL stock, worth $1.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35,430
Previous 34,062 4.02%
Holding current value
$1.23 Million
Previous $765,000 20.13%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $30,041 - $37,756
1,368 Added 4.02%
35,430 $919,000
Q2 2024

Aug 14, 2024

BUY
$20.34 - $23.73 $33,683 - $39,296
1,656 Added 5.11%
34,062 $765,000
Q1 2024

May 15, 2024

SELL
$20.17 - $23.93 $394,182 - $467,663
-19,543 Reduced 37.62%
32,406 $768,000
Q4 2023

Feb 14, 2024

BUY
$19.25 - $24.13 $192,962 - $241,879
10,024 Added 23.91%
51,949 $1.25 Million
Q3 2023

Nov 14, 2023

BUY
$19.04 - $22.74 $438,624 - $523,861
23,037 Added 121.97%
41,925 $916,000
Q2 2023

Aug 14, 2023

BUY
$18.17 - $20.48 $33,705 - $37,990
1,855 Added 10.89%
18,888 $360,000
Q1 2023

May 15, 2023

BUY
$16.3 - $19.41 $55,077 - $65,586
3,379 Added 24.75%
17,033 $330,000
Q4 2022

Feb 15, 2023

SELL
$14.96 - $17.39 $31,595 - $36,727
-2,112 Reduced 13.4%
13,654 $219,000
Q3 2022

Nov 16, 2022

BUY
$15.68 - $22.27 $154,777 - $219,827
9,871 Added 167.45%
15,766 $247,000
Q2 2022

Aug 23, 2022

SELL
$17.44 - $23.16 $8,004 - $10,630
-459 Reduced 7.22%
5,895 $123,000
Q2 2022

Aug 16, 2022

SELL
$17.44 - $23.16 $69,742 - $92,616
-3,999 Reduced 38.63%
6,354 $132,000
Q1 2022

May 16, 2022

SELL
$17.03 - $22.67 $2,520 - $3,355
-148 Reduced 1.41%
10,353 $235,000
Q4 2021

Feb 14, 2022

BUY
$15.84 - $21.88 $17,756 - $24,527
1,121 Added 11.95%
10,501 $192,000
Q3 2021

Nov 16, 2021

SELL
$16.3 - $21.14 $89,046 - $115,487
-5,463 Reduced 36.81%
9,380 $198,000
Q2 2021

Aug 16, 2021

SELL
$17.95 - $25.56 $111,236 - $158,395
-6,197 Reduced 29.45%
14,843 $270,000
Q1 2021

May 17, 2021

BUY
$20.53 - $25.22 $248,228 - $304,935
12,091 Added 135.11%
21,040 $475,000
Q4 2020

Feb 16, 2021

BUY
$18.39 - $24.8 $7,631 - $10,292
415 Added 4.86%
8,949 $180,000
Q3 2020

Nov 17, 2020

BUY
$20.67 - $26.94 $39,066 - $50,916
1,890 Added 28.45%
8,534 $209,000
Q2 2020

Aug 14, 2020

BUY
$16.46 - $27.42 $32,821 - $54,675
1,994 Added 42.88%
6,644 $156,000
Q1 2020

May 15, 2020

BUY
$14.46 - $21.8 $67,239 - $101,370
4,650 New
4,650 $77,000
Q2 2019

Aug 13, 2019

SELL
$18.93 - $24.75 $53,590 - $70,067
-2,831 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$19.6 - $24.76 $55,487 - $70,095
2,831 New
2,831 $67,000
Q4 2018

Feb 13, 2019

SELL
$13.65 - $21.8 $4,095 - $6,540
-300 Closed
0 $0
Q3 2018

Nov 15, 2018

BUY
$15.87 - $22.4 $4,761 - $6,720
300 New
300 $5,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.2B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.